Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

HEGER Zbynek POLANSKÁ Hana RODRIGO Miguel Angel Merlos GURÁŇ Roman KULICH Pavel KOPEL Pavel MASAŘÍK Michal ECKSCHLAGER Tomas STIBOROVA Marie KIZEK Rene ADAM Vojtech

Year of publication 2016
Type Article in Periodical
Magazine / Source Scientific Reports
MU Faculty or unit

Faculty of Medicine

Citation
Web http://www.nature.com/articles/srep33379
Doi http://dx.doi.org/10.1038/srep33379
Field Oncology and hematology
Keywords CANCER PROGRESSION; CELL-LINE; IN-VITRO; METALLOTHIONEIN; EXPRESSION; THERAPY; PROTEIN; URINE; NANOPARTICLES; TRAFFICKING
Attached files
Description Herein, we describe the preparation of liposomes with folate-targeting properties for the encapsulation of anti-sarcosine antibodies (antisarAbs@LIP) and sarcosine (sar@LIP). The competitive inhibitory effects of exogenously added folic acid supported the role of folate targeting in liposome internalization. We examined the effects of repeated administration on mice PC-3 xenografts. Sar@LIP treatment significantly increased tumor volume and weight compared to controls treated with empty liposomes. Moreover, antisarAbs@LIP administration exhibited a mild antitumor effect. We also identified differences in gene expression patterns post-treatment. Furthermore, Sar@LIP treatment resulted in decreased amounts of tumor zinc ions and total metallothioneins. Examination of the spatial distribution across the tumor sections revealed a sarcosine-related decline of the MT1X isoform within the marginal regions but an elevation after antisarAbs@LIP administration. Our exploratory results demonstrate the importance of sarcosine as an oncometabolite in PCa. Moreover, we have shown that sarcosine can be a potential target for anticancer strategies in management of PCa.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.